Switzerland (CH)

Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes (2022) Ndrepepa G, Neumann FJ, Menichelli M, Richardt G, Cassese S, Xhepa E, Kufner S, et al. Journal article Dynamical scaling of correlations generated by short- and long-range dissipation (2022) Seetharam K, Lerose A, Fazio R, Marino J Journal article Etiology, 3-Month Functional Outcome and Recurrent Events in Non-Traumatic Intracerebral Hemorrhage (2022) Goeldlin MB, Mueller A, Siepen BM, Mueller M, Strambo D, Michel P, Schaerer M, et al. Journal article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) Sinn BV, Untch M, Karn T, Van Mackelenbergh M, Huober J, Sychra K, Schmitt WD, et al. Conference contribution An Analysis of the Use Pattern of Hyperthermia (HT) in Combination with Radio(chemo)therapy or Chemotherapy in European HT Centers (2022) Ademaj A, Veltsista DP, Marder D, Haelg RA, Puric E, Brunner TB, Crezee H, et al. Conference contribution Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, et al. Conference contribution Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey (2022) Cardoso F, Rihani J, Aubel D, De Courcy J, Harmer V, Harbeck N, Casas A, et al. Conference contribution Irradiation of the locoregional Lymphatic Drainage Pathways of Breast Cancer: Is the prescribed Dose actually applied? A Planning Study by the DEGRO Breast Cancer Working Group (2022) Duma MN, Piroth M, Fastner G, Baumann R, Combs S, Dunst J, Feyer P, et al. Conference contribution